Literature DB >> 21926082

Abnormal vascular development in zebrafish models for fukutin and FKRP deficiency.

Alasdair J Wood1, Juliane S Müller, Catherine D Jepson, Steve H Laval, Hanns Lochmüller, Kate Bushby, Rita Barresi, Volker Straub.   

Abstract

Fukutin and fukutin-related protein (FKRP) are involved in the glycosylation of α-dystroglycan, a key receptor for basement membrane proteins. Aberrant α-dystroglycan glycosylation leads to a broad spectrum of disorders, ranging from limb girdle muscular dystrophy to Walker-Warburg syndrome. This is the first study investigating a role of fukutin and FKRP-mediated glycosylation in angiogenesis. Transgenic zebrafish expressing enhanced green fluorescent protein in blood vessels were treated with morpholino antisense oligonucleotides that blocked the expression of fukutin, FKRP and dystroglycan. All morphant fish showed muscle damage and vascular abnormalities at day 1 post-fertilization. Intersegmental vessels of somites failed to reach the dorsal longitudinal anastomosis and in more severe phenotypes retracted further or were in some cases even completely missing. In contrast, the eye vasculature was distorted in both fukutin and FKRP morphants, but not in dystroglycan morphants or control fish. The eye size was also smaller in the fukutin and FKRP morphants when compared with dystroglycan knockdown fish and controls. In general, the fukutin morphant fish had the most severe skeletal muscle and eye phenotype. Our findings suggest that fukutin and FKRP have functions that affect ocular development in zebrafish independently of dystroglycan. Despite anecdotal reports about vascular abnormalities in patients affected by dystroglycanopathies, the clinical relevance of such lesions remains unclear and should be subject to further review and investigations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926082     DOI: 10.1093/hmg/ddr426

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  11 in total

1.  Urologic and gastrointestinal symptoms in the dystroglycanopathies.

Authors:  Cameron D Crockett; Laura A Bertrand; Christopher S Cooper; Riad M Rahhal; Ke Liu; M Bridget Zimmerman; Steven A Moore; Katherine D Mathews
Journal:  Neurology       Date:  2015-01-07       Impact factor: 9.910

2.  A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.

Authors:  Peter R Serafini; Michael J Feyder; Rylie M Hightower; Daniela Garcia-Perez; Natássia M Vieira; Angela Lek; Devin E Gibbs; Omar Moukha-Chafiq; Corinne E Augelli-Szafran; Genri Kawahara; Jeffrey J Widrick; Louis M Kunkel; Matthew S Alexander
Journal:  JCI Insight       Date:  2018-09-20

Review 3.  Recent advancements in understanding mammalian O-mannosylation.

Authors:  M Osman Sheikh; Stephanie M Halmo; Lance Wells
Journal:  Glycobiology       Date:  2017-09-01       Impact factor: 4.313

4.  New MRI Findings in Fukuyama Congenital Muscular Dystrophy: Brain Stem and Venous System Anomalies.

Authors:  A Hirasawa-Inoue; N Sato; Y Shigemoto; Y Kimura; A Ishiyama; E Takeshita; M Mori-Yoshimura; Y Oya; Y Takahashi; H Komaki; H Matsuda; M Sasaki
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-21       Impact factor: 3.825

Review 5.  "Casting" light on the role of glycosylation during embryonic development: insights from zebrafish.

Authors:  Heather R Flanagan-Steet; Richard Steet
Journal:  Glycoconj J       Date:  2012-05-26       Impact factor: 2.916

Review 6.  Fukutin-Related Protein: From Pathology to Treatments.

Authors:  Carolina Ortiz-Cordero; Karim Azzag; Rita C R Perlingeiro
Journal:  Trends Cell Biol       Date:  2020-12-01       Impact factor: 20.808

7.  FKRP-dependent glycosylation of fibronectin regulates muscle pathology in muscular dystrophy.

Authors:  A J Wood; C H Lin; M Li; K Nishtala; S Alaei; F Rossello; C Sonntag; L Hersey; L B Miles; C Krisp; S Dudczig; A J Fulcher; S Gibertini; P J Conroy; A Siegel; M Mora; P Jusuf; N H Packer; P D Currie
Journal:  Nat Commun       Date:  2021-05-19       Impact factor: 14.919

8.  Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan.

Authors:  Tony Roscioli; Erik-Jan Kamsteeg; Karen Buysse; Isabelle Maystadt; Jeroen van Reeuwijk; Christa van den Elzen; Ellen van Beusekom; Moniek Riemersma; Rolph Pfundt; Lisenka E L M Vissers; Margit Schraders; Umut Altunoglu; Michael F Buckley; Han G Brunner; Bernard Grisart; Huiqing Zhou; Joris A Veltman; Christian Gilissen; Grazia M S Mancini; Paul Delrée; Michèl A Willemsen; Danijela Petković Ramadža; David Chitayat; Christopher Bennett; Eamonn Sheridan; Els A J Peeters; Gita M B Tan-Sindhunata; Christine E de Die-Smulders; Koenraad Devriendt; Hülya Kayserili; Osama Abd El-Fattah El-Hashash; Derek L Stemple; Dirk J Lefeber; Yung-Yao Lin; Hans van Bokhoven
Journal:  Nat Genet       Date:  2012-05       Impact factor: 38.330

9.  Dystroglycan and dystroglycanopathies: report of the 187th ENMC Workshop 11-13 November 2011, Naarden, The Netherlands.

Authors:  Susan C Brown; Steve J Winder
Journal:  Neuromuscul Disord       Date:  2012-03-19       Impact factor: 4.296

10.  Insights from molecular dynamics simulations: structural basis for the V567D mutation-induced instability of zebrafish alpha-dystroglycan and comparison with the murine model.

Authors:  Davide Pirolli; Francesca Sciandra; Manuela Bozzi; Bruno Giardina; Andrea Brancaccio; Maria Cristina De Rosa
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.